Are We Closer To Curing Depression With This Drug?
Psilocybin Mushrooms, or more commonly known as “magic mushrooms” are listed as Schedule 1 Drugs according to US Federal Law. This means that this substance has a high potential for abuse, has no currently accepted medical treatment use in the US, or has a lack of accepted safety for use under medical supervision. US Law states that no prescriptions may be written for these types of substances and these are not readily available for clinical use.
Recent studies, however, are challenging the notion of these drugs. King’s College London Researchers and healthcare company COMPASS Pathways executed a randomized placebo-controlled phase 1 trial of psylocibin and has assessed its safety, finding no adverse effects in its usage.
The group presented at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), revealing their method of dividing 90 healthy volunteers into three groups who received a placebo, 10 milligrams of the drug, or 25 milligrams of it. They discovered that none of the volunteers who received psylocibin reported negative results on their emotional state or cognitive function; only experiencing sensory perception changes or mood boosts.
Previous studies showed the effectiveness of psilocybin in treating depression of the unconventional kind. Other research also link the possibility of eradicating addictions such as drinking and smoking when being exposed to the substance in a clinical manner. For the moment, however, we still have to wait until trials are done before we can benefit from this research.
Want more technology tips that help you in your day-to-day practice? in Science and Technology! Pay us a visit at www.dostv.ph or you can check out and like us at facebook.com/dostvph.
Subscribe and be a #DOSTvarka at www.youtube.com/dostvscienceforthepeople See you on Instagram and Twitter, too @dostvph.
